DLG
ATNM icon

Daniel L. Goodwin’s Actinium Pharmaceuticals ATNM Stock Holding History

Daniel L. Goodwin’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$60K – 104
2021
Q4 		$60K Hold
10,000
– – 0.03% 103
2021
Q3 		$88K Hold
10,000
– – 0.04% 109
2021
Q2 		$80K Sell
10,000
-10,000
-50% -$78.5K 0.04% 113
2021
Q1 		$152K Hold
20,000
– – 0.08% 101
2020
Q4 		$156K Buy
+20,000
New +$217K 0.09% 93

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Daniel L. Goodwin's ATNM Position: Q1 2022 in Review

Daniel L. Goodwin sold out of Actinium Pharmaceuticals (ATNM) in Q1 2022, closing a stake of 10,000 shares — an estimated $60K sold.

Daniel L. Goodwin first reported a position in ATNM in Q4 2020 and held it in 5 quarters. The position peaked at $156K in Q4 2020. 38 funds tracked by Wall St. Rank hold ATNM as of Q1 2022.

  • Daniel L. Goodwin reported no remaining Actinium Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Daniel L. Goodwin sold 10,000 Actinium Pharmaceuticals shares in Q1 2022, an estimated $60K.
  • Daniel L. Goodwin first reported a position in Actinium Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Daniel L. Goodwin's Actinium Pharmaceuticals position peaked at $156K in Q4 2020.
  • 38 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2022.

Based on Daniel L. Goodwin's 13F filing for Q1 2022, filed 21 Apr 2022.